Literature DB >> 26266002

Retrospective study evaluating the performance of a first-trimester combined screening for trisomy 21 in an Italian unselected population.

Francesco Padula1, Pietro Cignini1, Diana Giannarelli2, Cristiana Brizzi1, Claudio Coco1, Laura D'Emidio1, Elsa Giorgio1, Maurizio Giorlandino1, Lucia Mangiafico1, Marialuisa Mastrandrea1, Vincenzo Milite1, Luisa Mobili1, Cinzia Nanni1, Raffaella Raffio1, Cinzia Taramanni1, Roberto Vigna1, Alvaro Mesoraca3, Domenico Bizzoco3, Ivan Gabrielli3, Gianluca Di Giacomo3, Maria Antonietta Barone3, Antonella Cima3, Francesca Romana Giorlandino3, Sabrina Emili3, Marina Cupellaro3, Claudio Giorlandino1.   

Abstract

OBJECTIVES: to assess the performance of a combined first-trimester screening for trisomy 21 in an unselected Italian population referred to a specialized private center for prenatal medicine.
METHODS: a retrospective validation of first-trimester screening algorithms [risk calculation based on maternal age and nuchal translucency (NT) alone, maternal age and serum parameters (free β-hCG and PAPP-A) alone and a combination of both] for fetal aneuploidies evaluated in an unselected Italian population at Artemisia Fetal-Maternal Medical Centre in Rome. All measurements were performed between 11(+0) and 13(+6) weeks of gestation, between April 2007 and December 2008.
RESULTS: of 3,610 single fetuses included in the study, we had a complete follow-up on 2,984. Fourteen of 17 cases of trisomy 21 were detected when a cut-off of 1:300 was applied [detection rate (DR) 82.4%, 95% confidence interval (CI) 64.2-100; false-positive rate (FPR) 4.7%, 95% CI 3.9-5.4; false-negative rate (FNR) 17.6%, 95% CI 0-35.8%].
CONCLUSION: in our study population the detection rate for trisomy 21, using the combined risk calculation based on maternal age, fetal NT, maternal PAPP-A and free β-hCG levels, was superior to the application of either parameter alone. The algorithm has been validated for first trimester screening in the Italian population.

Entities:  

Keywords:  Down Syndrome; SCA-Test; first trimester screening; nuchal translucency

Year:  2014        PMID: 26266002      PMCID: PMC4510564     

Source DB:  PubMed          Journal:  J Prenat Med        ISSN: 1971-3282


  38 in total

1.  A critical evaluation of sonar "crown-rump length" measurements.

Authors:  H P Robinson; J E Fleming
Journal:  Br J Obstet Gynaecol       Date:  1975-09

2.  Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14-week scan.

Authors:  S Cicero; G Rembouskos; H Vandecruys; M Hogg; K H Nicolaides
Journal:  Ultrasound Obstet Gynecol       Date:  2004-03       Impact factor: 7.299

3.  Position Statement from the Italian College of Fetal Maternal Medicine: Non-invasive prenatal testing (NIPT) by maternal plasma DNA sequencing.

Authors: 
Journal:  J Prenat Med       Date:  2013-04

4.  A re-evaluation of the influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.

Authors:  K Spencer; N J Cowans; C E Spencer; N Achillea
Journal:  Prenat Diagn       Date:  2010-10       Impact factor: 3.050

5.  Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.

Authors:  K H Nicolaides; K Spencer; K Avgidou; S Faiola; O Falcon
Journal:  Ultrasound Obstet Gynecol       Date:  2005-03       Impact factor: 7.299

6.  Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.

Authors:  Mohammed-Salleh M Ardawi; Hasan A Nasrat; Abdulrahim A Rouzi; Mohammed H Qari; Mohammed H Al-Qahtani; Adel M Abuzenadah
Journal:  Prenat Diagn       Date:  2007-04       Impact factor: 3.050

7.  Improved prenatal aneuploidy screening using the novel advanced first-trimester screening algorithm: a multicenter study of 10,017 pregnancies.

Authors:  Peter Schmidt; Cindy Hörmansdörfer; Michael Pruggmayer; Christian Schütte; Armin Neumann; Andreas Gerritzen; Bernhard Vaske; Peter Hillemanns; Alexander Scharf
Journal:  J Clin Ultrasound       Date:  2008-09       Impact factor: 0.910

8.  Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.

Authors:  K H Nicolaides; G Azar; D Byrne; C Mansur; K Marks
Journal:  BMJ       Date:  1992-04-04

9.  Examination of a first-trimester Down syndrome screening concept on a mix of 11,107 high- and low-risk patients at a private center for prenatal medicine in Germany.

Authors:  Michael Schaelike; Maria Kossakiewicz; Andreas Kossakiewicz; Ralf L Schild
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2009-04-11       Impact factor: 2.435

10.  Screening for Down's syndrome in the first trimester: combined risk calculation, methodology, and validation of a web-based system.

Authors:  Marius Kublickas; Jennifer Crossley; David Aitken
Journal:  Acta Obstet Gynecol Scand       Date:  2009       Impact factor: 3.636

View more
  1 in total

1.  Single Nucleotide Polymorphism-Based Noninvasive Prenatal Testing: Experience in India.

Authors:  Ishwar Chander Verma; Ratna Puri; Eswarachary Venkataswamy; Tulika Tayal; Sheela Nampoorthiri; Chitra Andrew; Madhulika Kabra; Rashmi Bagga; Mamatha Gowda; Meenu Batra; Sridevi Hegde; Anita Kaul; Neerja Gupta; Pallavi Mishra; Jayshree Ganapathi Subramanian; Shruti Lingaiah; Riyaz Akhtar; Francis Kidangan; R Chandran; C Kiran; G R Ravi Kumar; V L Ramprasad; Priya Kadam
Journal:  J Obstet Gynaecol India       Date:  2018-01-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.